{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-004556","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2026-07-28T18:30:39+00:00","discovered_at":"2026-07-28T18:31:00.251212+00:00","generated_at":"2026-07-28T18:31:06.124445+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BioNexus advances VitaGuard MRD rollout in SE Asia after China visit; targets 2026 deployment","bullets":["Working visit to Tongshu Gene facilities in Shanghai and Changzhou; reviewed implementation for SE Asia under license.","VitaGuard is a tumor-naive fixed-panel liquid biopsy for MRD; currently in paid commercial use in China.","BioNexus holds exclusive license for 10 SE Asian markets (pop. 680M); also owns ~15% of Fidelion holding international rights.","Target cost per test under $300; initial deployment targeted in select SE Asian medical hubs during 2026.","Fidelion in discussions with partners for markets outside SE Asia; no definitive agreement yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-004556","json":"https://secwatch.observer/filing/0001477932-26-004556.json","markdown":"https://secwatch.observer/filing/0001477932-26-004556.md","text":"https://secwatch.observer/filing/0001477932-26-004556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793226004556/0001477932-26-004556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793226004556/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-28T18:31:06.124445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}